Needham has raised its price target on Globus Medical Inc. to $114 from $112 while affirming a Buy rating on the stock. At the time of the analyst update, the share price stood at $91.88. InvestingPro analysis lists the stock among its Most Undervalued securities, assigning a Fair Value of $103.42.
The lift in Needham’s target follows Globus Medical’s fourth-quarter 2025 period, where revenue was consistent with the company’s preannouncement and earnings per share outperformed consensus expectations. Management subsequently increased its earnings per share guidance for 2026. Needham noted the potential for additional upward revisions to earnings estimates over the near term.
Market data tracked by InvestingPro Tips show seven analysts have already raised earnings estimates for the upcoming period, and the company retains a "GREAT" financial health designation with a score of 3.6 out of 5. Operationally, U.S. Spine growth held steady at 10%, which outpaced broader market growth rates. International Spine delivered a record quarter, and the company expects international growth to quicken through 2026.
On a trailing-twelve-month basis, Globus Medical’s revenue expanded 16.65%. The stock has also produced a strong market performance recently, returning 49.69% over the past six months. The company continues to report a robust robot pipeline, although the mix of placements could weigh on Enabling Tech’s growth during the current year.
In more detailed results, Globus Medical reported fourth-quarter 2025 sales of $826.4 million, a 25% increase excluding foreign exchange effects, surpassing prior estimates near $823 million. Core revenues were reported at $727 million, an increase of 9.4%.
Investor and analyst reactions were broadly favorable after those results. Jefferies raised its price target to $120 while keeping a Buy stance. Truist Securities lifted its target to $115, maintaining its Buy rating as well. Needham not only adjusted its target but upgraded Globus Medical from Hold to Buy, pointing to margin expansion and forecasting further margin improvement in 2026.
Other firms also adjusted their coverage: TD Cowen initiated coverage with a Buy rating and a $110 price target, highlighting potential for continued outperformance, and Canaccord Genuity raised its target to $112 and maintained a Buy recommendation after preliminary fourth-quarter results exceeded both Canaccord’s and consensus expectations.
Collectively, these analyst moves reflect a generally positive sentiment around Globus Medical’s recent operating performance, margin trajectory and international growth prospects, while also flagging some near-term pressure areas such as placement mix within the company’s enabling technologies business.